Mavrilimumab
Based on 1 Customer Validation
Mavrilimumab (CAM 3001) is a monoclonal antibody that binds to the α subunit of the granulocyte-macrophage colony stimulating factor (GM-CSF) receptor and blocks intracellular signalling downstream of GM-CSF. GM-CSF might be a mediator of the hyperactive inflammatory response associated with respiratory failure and death.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 98.37%
- CAS No.: 1085337-57-0
- 분자량:143.168 kDa
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Human IgG4 lambda
Human
CSF2Ra/GM-CSFRa/CD116
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Cynomolgus monkey models[2]
-
Dosage:3-100 mg/kg
-
Administration:iv, once a week for at least 11 weeks
-
Result:Produced foam cells in the lungs.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG4 lambda2
ELISA, FACS, Functional assay
-
Loaded Mavrilimumab on AHC2 biosensor, can bind GM-CSF R alpha Protein, Human (HEK293, His, HY-P7783) with an affinity constant of 7.867E-10 M as determined in BLI assay. -
Flow Cytometry analysis of Hela cells labelling GM-CSFRa (red) with Mavrilimumab (anti-GM-CSFRa) (HY-P99031). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG4 (S228P) lambda1(HY-P99987). Black-Unlabelled control, cells without incubation with primary antibody.
Chemical Information
-
CAS No. 1085337-57-0
-
Appearance Liquid
-
분자량 143.168 kDa
-
Color Colorless to light yellow
-
SMILES
[Mavrilimumab]
-
Synonyms
CAM 3001
-
선적
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
-
Data Sheet (259 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Paul C Cremer, et al. Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial. Lancet Rheumatol. 2021 Jun;3(6):e410-e41 [Content Brief]
[2]. Ryan PC, et al., Nonclinical safety of mavrilimumab, an anti-GMCSF receptor alpha monoclonal antibody, in cynomolgus monkeys: relevance for human safety. Toxicol Appl Pharmacol. 2014 Sep 1;279(2):230-9. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)